247 related articles for article (PubMed ID: 36070068)
1. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy.
Chen D; Qin H; Deng G; Wang Q; Wang H; Liu X
Clin Transl Oncol; 2023 Jan; 25(1):226-235. PubMed ID: 36070068
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy.
Wang Q; Tan X; Deng G; Fu S; Li J; Li Z
BMC Pulm Med; 2022 Mar; 22(1):75. PubMed ID: 35241046
[TBL] [Abstract][Full Text] [Related]
3. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
4. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations.
Qin H; Ke J; Dong S; Li H; Zhu K; Fu S; Shao Q; Li Z
BMC Cancer; 2022 Sep; 22(1):1012. PubMed ID: 36153486
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
8. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations.
Li H; Wang G; Zhang H; Song X; Cao J; Zhang X; Xue R; Wang W; Jia S; Li Z
Genes Immun; 2019 Jul; 20(6):455-461. PubMed ID: 30410015
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
11. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.
Yucel S; Bilgin B
J Oncol Pharm Pract; 2021 Jan; 27(1):71-77. PubMed ID: 32248739
[TBL] [Abstract][Full Text] [Related]
12. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy.
Chen J; Huang W; Xu X; Fan S; Zhang Q; Li X; Zeng Z; He J
Front Oncol; 2023; 13():1076428. PubMed ID: 37251953
[TBL] [Abstract][Full Text] [Related]
14. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
Xu S; Cao S; Yu Y
J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
[TBL] [Abstract][Full Text] [Related]
15. High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.
Zhao X; Zhang N; Zhang H; Liu P; Ma J; Hu C; Liu X; Hou T
Medicine (Baltimore); 2020 Nov; 99(46):e23150. PubMed ID: 33181687
[TBL] [Abstract][Full Text] [Related]
16. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
17. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer.
Gao Y; Zhang H; Li Y; Wang D; Ma Y; Chen Q
Clin Chim Acta; 2018 Sep; 484():272-277. PubMed ID: 29860033
[TBL] [Abstract][Full Text] [Related]
18. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
19. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
20. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.
Fan R; Chen Y; Xu G; Pan W; Lv Y; Zhang Z
Front Oncol; 2023; 13():996312. PubMed ID: 37077828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
